These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 16810619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. When and how to treat essential thrombocythemia.
    Barbui T, Finazzi G.
    N Engl J Med; 2005 Jul 07; 353(1):85-6. PubMed ID: 16000360
    [No Abstract] [Full Text] [Related]

  • 5. Long-term management of thrombocytosis in essential thrombocythaemia.
    Birgegård G.
    Ann Hematol; 2009 Jan 07; 88(1):1-10. PubMed ID: 18629498
    [Abstract] [Full Text] [Related]

  • 6. Anagrelide: what was new in 2004 and 2005?
    Petrides PE.
    Semin Thromb Hemost; 2006 Jun 07; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of essential thrombocythemia].
    Alvarez-Larrán A, Cervantes F, Besses C.
    Med Clin (Barc); 2013 Sep 21; 141(6):260-4. PubMed ID: 23490491
    [Abstract] [Full Text] [Related]

  • 8. Pharmacotherapy of essential thrombocythaemia: economic considerations.
    Griesshammer M, Langer C.
    Expert Opin Pharmacother; 2003 Sep 21; 4(9):1499-505. PubMed ID: 12943479
    [Abstract] [Full Text] [Related]

  • 9. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Samuelson B, Chai-Adisaksopha C, Garcia D.
    J Thromb Thrombolysis; 2015 Nov 21; 40(4):474-9. PubMed ID: 25894476
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
    Golub R, Adams J, Dave S, Bennett CL.
    Semin Oncol; 2002 Jun 21; 29(3 Suppl 10):28-32. PubMed ID: 12096355
    [Abstract] [Full Text] [Related]

  • 12. [Essential thrombocythemia: conventional therapy].
    Grossi A, Vannucchi AM, Longo G, Rafanelli D, Rossi Ferrini P.
    Haematologica; 1991 Jun 21; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
    Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian JJ, Coll R, Smith J, Abhyankar B, Birgegård G.
    Haematologica; 2014 Apr 21; 99(4):679-87. PubMed ID: 24334294
    [Abstract] [Full Text] [Related]

  • 16. Pharmacotherapy of essential thrombocythemia.
    Gangat N, Tefferi A.
    Expert Opin Pharmacother; 2008 Jul 21; 9(10):1679-85. PubMed ID: 18570601
    [Abstract] [Full Text] [Related]

  • 17. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C, Sol EB, Malarme M, Noubouossie D, Demulder AC.
    Clin Ther; 2009 Nov 21; 31(11):2559-64. PubMed ID: 20110000
    [Abstract] [Full Text] [Related]

  • 18. Essential thrombocythaemia.
    Double G, Harrison C.
    Hematology; 2015 Mar 21; 20(2):119-20. PubMed ID: 25715049
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.